Биологическая активность
Brentuximab is a моноклональный антитело targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the антитело-препарат conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells.
Оригинал на английском
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells.
Химические свойства
- CAS №
- 2088770-90-3 pH value: Corresponds to reference standard: PASS Non-reduced CE-SDS: >95% SEC-HPLC: >95% Isoelectric Point: Corresponds to reference standard Osmolality: Corresponds to reference standard: PASS Peptide mapping: Corresponds to reference standard: PASS N-terminal sequence: Corresponds to reference standard: PASS
Безопасность и документация
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.